Quipt Home Medical (QIPT) Corporate presentation summary

Financial and operational highlights

• FY2024 revenue reached $245.9M with adjusted EBITDA of $57.9M and $35.4M in cash flow from operations.

• Over 850,000 annual deliveries, 325,000+ patient lives served, and 36,000+ referring physicians.

• 81% of revenue is recurring, with a diversified product and payor mix.

• Q3 2025 cash flow from operations was $27.9M, with $46.6M in liquidity and 1.5x net debt to EBITDA leverage.

• Consistent demand driven by aging demographics and chronic conditions, supporting robust organic growth.

Growth strategy and expansion

• Targets 8-10% annual organic growth, leveraging sales force and technology for operational efficiency.

• Focuses on synergistic acquisitions, expanding into regions with high COPD prevalence and underpenetrated markets.

• Recent acquisitions include Hart Medical Equipment and Ballad Health Medical Equipment, expanding reach and revenue base.

• Maintains a conservative balance sheet with leverage below 2.5x net debt to EBITDA.

• Emphasizes economies of scale and margin consistency through technology and integration.

Market positioning and business model

• Operates over 150 locations in 27 states, solidifying Midwest and Southeast presence.

• End-to-end product solution integrates sales, delivery, education, and revenue cycle for patient satisfaction.

• Diversified product mix includes ventilation, sleep therapy, oxygen, mobility, and home medical equipment.

• Connected healthcare ecosystem with remote patient monitoring and live treatment plan tracking.

• In-home delivery and certified respiratory therapists ensure compliance and care quality.